Page 245 of 439: studies 2,441 to 2,450 of 4,389, newest first. Back to the psilocybin overview
July 27, 2022 Rebekah Senanayake
<p>Disruptions to the sense of self are dotted across cultures and times in rituals involving hallucinogens, sensory deprivation, trance possession, and meditation. Much of the research on the self or “ego” suggests that the self is a complicated, multi-faceted entity and that there are many aspects that hold together our ego. Yet, current measurements on ego-dissolution focus on a narrow...
July 7, 2022 Richard J. Zeifman, Meg J. Spriggs, Hannes Kettner et al. 13 citations preprint
Background: The Relaxed Beliefs Under pSychedelics (REBUS) model proposes that serotonergic psychedelics decrease the precision weighting of neurobiologically-encoded beliefs, and offers a unified account of the acute and therapeutic action of psychedelics. Although REBUS has received some neuroscientific support, little research has examined its psychological validity. We conducted a...
International Journal of Bipolar Disorders July 5, 2022 Oliver G. Bosch, Simon Halm, Erich Seifritz 35 citations
Abstract This is a narrative review about the role of classic and two atypical psychedelics in the treatment of unipolar and bipolar depression. Since the 1990s, psychedelics experience a renaissance in biomedical research. The so-called classic psychedelics include lysergic acid diethylamide (LSD), psilocybin, mescaline and ayahuasca. Characteristic effects like alterations in sensory...
Journal of Neurochemistry July 1, 2022 Hannah N Saeger, David E. Olson 59 citations
Psychedelics are increasingly being recognized for their potential to treat a wide range of brain disorders including depression, post-traumatic stress disorder (PTSD), and substance use disorder. Their broad therapeutic potential might result from an ability to rescue cortical atrophy common to many neuropsychiatric and neurodegenerative diseases by impacting neurotrophic factor gene...
Neuroscience & Biobehavioral Reviews July 1, 2022 Drummond E-Wen Mcculloch, Gitte Moos Knudsen, Frederick Streeter Barrett et al. 14 citations
Clinical research into serotonergic psychedelics is expanding rapidly, showing promising efficacy across myriad disorders. Resting-state functional magnetic resonance imaging (rs-fMRI) is a commonly used strategy to identify psychedelic-induced changes in neural pathways in clinical and healthy populations. Here we, a large group of psychedelic imaging researchers, review the 42 research...
Cureus June 28, 2022 Ann M. Inouye, Aaron Wolfgang 5 citations
The Food and Drug Administration (FDA) granted breakthrough therapy status to 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) in 2017 due to preliminary evidence supporting its efficacy and safety in treating post-traumatic stress disorder (PTSD). A series of six phase-II clinical trials studying MDMA-AT for treatment-resistant PTSD found that 54% of MDMA-AT full-dose...
Frontiers in Pharmacology June 28, 2022 Nataliya S. Vorobyeva, Alena A. Kozlova 16 citations
Classical psychedelics represent a family of psychoactive substances with structural similarities to serotonin and affinity for serotonin receptors. A growing number of studies have found that psychedelics can be effective in treating various psychiatric conditions, including post-traumatic stress disorder, major depressive disorder, anxiety, and substance use disorders. Mental health disorders...
Journal of Psychedelic Studies June 9, 2022 Annie M. Mccartney, Hugh McGovern, Alexander de Foe 8 citations
Abstract Psychedelic substances such as psilocybin and ketamine may represent the future of antidepressant treatment, due to their rapid and prolonged effects on mood and cognition. The current body of psychedelic research has focused on administration and treatment within a psychiatric context. Here, instead, we put to the test the contention that it is necessary to evaluate the current state...
Medicine, Health Care, and Philosophy June 1, 2022 Riccardo Miceli Mcmillan, Christopher Jordens 15 citations
Psychedelic-assisted Psychotherapy (PAP) combines the use of psychedelic compounds, such as psilocybin, with psychotherapy. PAP has shown some promise as a novel treatment for Major Depressive Disorder (MDD), and empirical research suggests that its efficacy turns on the altered states induced by psychedelic compounds. In this paper we draw on the literature of phenomenology to explain the...
European Psychiatry June 1, 2022 Jaime Rodrigues, O. Nombora, Luiz Vicente Ribeiro 1 citation
Introduction Obsessive Compulsive Disorder (OCD) is a psychiatric disorder associated with suffering and disability. The serotoninergic system is implicated in the neurobiological processes of OCD and serotonin reuptake inhibitors (SRIs) are the first-line treatment. However, clinical improvement after starting SRIs can take long and patients may not fully recover. Meanwhile, recent data...